Oncology – Breast
Study identifies which treatments are associated with an increased risk of heart disease among women with breast cancer.
13 Apr, 2022 | 10:00h | UTCRisk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Major study links breast cancer treatment with increased risk of cardiovascular disease – Fred Hutch
Commentary on Twitter
Great case-control study in a modern cohort evaluating long-term cardiovascular disease after #breastcancer treatment. HR for heart failure/cardiomyopathy higher for anthracyclines (HR=1.84) and herceptin (HR=2.53) than for #radiotherapy (HR=1.38). #bcsmhttps://t.co/ZEVfbwlepr
— Shane Stecklein, MD, PhD (@shanestecklein) April 8, 2022
M-A: Sentinel lymph node biopsy in patients with ductal carcinoma in situ.
11 Apr, 2022 | 00:46h | UTC
Commentary on Twitter
What is the role of #slnb in #dcis?
This #systematicreview included 16 studies/4388 patients.#DCIS associated with v. low rates of axillary + disease.
Palpable disease, tumour necrosis, g3 DCIS may predict +ve SLNB.#some4surgery #breastcancer https://t.co/oNR25Nu9KN pic.twitter.com/orlMF73300— BJS Open (@BjsOpen) April 8, 2022
Internal mammary node irradiation in patients with node-positive early breast cancer: fifteen-year results from the Danish breast cancer group internal mammary node study.
11 Apr, 2022 | 00:41h | UTCInternal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study https://t.co/fwtVF5Z6g7
— Lise Bech Jellesmark Thorsen (@Lise_BJT) April 9, 2022
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy.
8 Apr, 2022 | 09:43h | UTC
Cohort study: Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy.
7 Apr, 2022 | 08:09h | UTC
Commentary on Twitter
Out now @JCO_ASCO huge effort of our team and @TILsWorkGroup: Excellent prognosis of TNBC pts with high TILs even without chemo! Chemo de-escalation trials urgently needed! # bcsm https://t.co/42eUZaA2vo
— MarleenKokLab (@lab_kok) March 31, 2022
M-A of randomized trials: Effects of capecitabine as part of neo-/adjuvant chemotherapy in patients with breast cancer.
5 Apr, 2022 | 08:06h | UTCEffects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients – European Journal of Cancer (link to abstract – $ for full-text)
Study Commentary: Older women with breast cancer chose less aggressive treatment when they used a decision aid.
1 Apr, 2022 | 08:16h | UTC
Commentary on Twitter
Open access in May's BJS: Bridging the age gap in breast cancer: two decision support interventions for older women with operable breast cancer https://t.co/s70uEVyAxU @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs pic.twitter.com/IUuiUldUTS
— BJS (@BJSurgery) June 11, 2021
RCT: Trastuzumab Deruxtecan vs. Trastuzumab Emtansine for breast cancer.
28 Mar, 2022 | 08:48h | UTCTrastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Trastuzumab Deruxtecan Ups PFS in HER2+ Metastatic Breast Cancer – HealthDay
Commentary on Twitter
In patients with metastatic HER2+ breast cancer that progressed after primary therapy, treatment with trastuzumab deruxtecan resulted in a higher response rate and longer progression-free survival than trastuzumab emtansine. https://t.co/R5suUeMLgE pic.twitter.com/yMiGrJw71U
— NEJM (@NEJM) March 24, 2022
Long-term longitudinal patterns of patient-reported fatigue after breast cancer: a group-based trajectory analysis.
22 Mar, 2022 | 08:29h | UTC
Commentary on Twitter
https://twitter.com/PTarantinoMD/status/1503916087829794816
The incidence of breast cancer recurrence 10-32 years after primary diagnosis.
22 Mar, 2022 | 08:12h | UTC
M-A: Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer.
16 Mar, 2022 | 08:30h | UTC
RCT: Overall survival with Ribociclib plus Letrozole in advanced breast cancer.
11 Mar, 2022 | 09:47h | UTCOverall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Adding Ribociclib to Letrozole Prolongs Survival in Advanced Breast Cancer – HealthDay
Mapping systematic reviews of breast cancer survivorship interventions.
10 Mar, 2022 | 10:16h | UTC
Commentary on Twitter
🌐 Despite vast volume, review-level #BreastCancer #survivorship research is unevenly distributed and siloed. Strategic planning of future research, in consultation with survivors, is needed. ➡️ https://t.co/pxMp5XK8B8 #JCO #BCSM @EmmaBKemp1 #survonc pic.twitter.com/TRjOEJQbrw
— Journal of Clinical Oncology (@JCO_ASCO) March 5, 2022
RCT: Efficacy of HD201 vs. referent Trastuzumab in patients With ERBB2-positive breast cancer treated in the neoadjuvant setting.
9 Mar, 2022 | 08:22h | UTC
Commentary on Twitter
https://twitter.com/JAMAOnc/status/1499791783735271426
New research finds breast cancer overdiagnosis not as common as previously thought.
7 Mar, 2022 | 00:36h | UTCEstimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort – Annals of Internal Medicine (link to abstract – $ for full-text)
Breast cancer overdiagnosis may not happen as frequently as previously thought – ACP Internist
Cancer risks other than female breast and ovarian cancers associated with BRCA1 and BRCA2 pathogenic variants.
3 Mar, 2022 | 08:14h | UTCCancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology
Commentary: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge
RCT: Referral for early, supported exercise after breast cancer surgery improves shoulder function and health-related quality of life.
1 Mar, 2022 | 08:50h | UTCFull Report: Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT – Health Technology Assessment
Screening Algorithms in Dense Breasts: AJR Expert Panel Narrative Review.
24 Feb, 2022 | 10:11h | UTC
M-A: Immune checkpoint inhibitors combined with chemotherapy compared with chemotherapy alone for triple-negative breast cancer.
17 Feb, 2022 | 08:13h | UTC
Aromatase inhibitors vs. tamoxifen in premenopausal women with estrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomized trials
13 Feb, 2022 | 21:32h | UTCCommentaries:
Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer – HealthDay
RCT: Event-free survival with pembrolizumab in early triple-negative breast cancer.
11 Feb, 2022 | 08:35h | UTCEvent-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary (before publication): KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer – The ASCO Post
Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update.
10 Feb, 2022 | 08:33h | UTC
RCT: Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer–Related Lymphedema.
4 Feb, 2022 | 08:35h | UTC
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicenter pooled analysis of 5161 patients.
2 Feb, 2022 | 08:22h | UTC
Observational Study: Same-day mastectomy and axillary lymph node dissection seems safe for most patients with breast cancer.
1 Feb, 2022 | 08:38h | UTC